Avian-flu vaccine makers receive immunity from liability lawsuits

Share this article:
The Bush administration has triggered a provision of a 2005 law that protects companies producing vaccines or drugs made in connection with avian-flu from product-liability lawsuits. The law gives the Secretary of Health and Human Services power to grant immunity to vaccine and drug makers in the event of a risk to public health. In a directive last week, HHS invoked the clause, “based on a credible risk that an avian- influenza virus spreads and evolves into a strain capable of causing a pandemic of human influenza.” Bill Hall, an HHS spokesman told The Wall Street Journal, the agency’s declaration “allows us to remove the remaining barrier to building up our domestic capacity to manufacturers of vaccines in a flu pandemic.” Hall denied to The Journal that the move reflected heightened concern about the avian flu. Rather, he said, “It was a precautionary step.” As part of a plan to spur development of experimental vaccines and other countermeasures against bioterrorism threats, Congress passed the bill in late 2005 to provide liability protection to those vaccine makers. The measure was signed by President Bush in December 2005 but was met with criticism by some trial lawyers and lawmakers as a giveaway to drug companies.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...